[go: up one dir, main page]

RU2016146594A - Средство для лечения деменции различной этиологии - Google Patents

Средство для лечения деменции различной этиологии Download PDF

Info

Publication number
RU2016146594A
RU2016146594A RU2016146594A RU2016146594A RU2016146594A RU 2016146594 A RU2016146594 A RU 2016146594A RU 2016146594 A RU2016146594 A RU 2016146594A RU 2016146594 A RU2016146594 A RU 2016146594A RU 2016146594 A RU2016146594 A RU 2016146594A
Authority
RU
Russia
Prior art keywords
dementia
treatment
various etiologies
ethyl
etiologies
Prior art date
Application number
RU2016146594A
Other languages
English (en)
Other versions
RU2016146594A3 (ru
Inventor
Сергей Олегович Бачурин
Рахимджан Ахметджанович Розиев
Валентин Георгиевич Ненайденко
Константин Владимирович Анохин
Анна Яковлевна Гончарова
Кенес Тагаевич Еримбетов
Екатерина Валерьевна Бондаренко
Ксения Юрьевна Власова
Original Assignee
Общество С Ограниченной Ответственностью "Биофарм-Меморейн"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Биофарм-Меморейн" filed Critical Общество С Ограниченной Ответственностью "Биофарм-Меморейн"
Priority to RU2016146594A priority Critical patent/RU2016146594A/ru
Priority to PCT/RU2017/050122 priority patent/WO2018097768A1/ru
Priority to US16/464,283 priority patent/US20200281908A1/en
Priority to EA201991337A priority patent/EA201991337A1/ru
Publication of RU2016146594A publication Critical patent/RU2016146594A/ru
Publication of RU2016146594A3 publication Critical patent/RU2016146594A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (1)

  1. Средство с направленной доставкой для лечения деменции различной этиологии, представляющее собой липосомальную композицию метил-4-[2-оксо-1,2-бис[[2-(4-пиридинил)этил]амино]этил]-бензоат сукцината, полученную пленочным способом с последующей гидратацией и обработкой ультразвуком.
RU2016146594A 2016-11-28 2016-11-28 Средство для лечения деменции различной этиологии RU2016146594A (ru)

Priority Applications (4)

Application Number Priority Date Filing Date Title
RU2016146594A RU2016146594A (ru) 2016-11-28 2016-11-28 Средство для лечения деменции различной этиологии
PCT/RU2017/050122 WO2018097768A1 (ru) 2016-11-28 2017-11-28 Средство для лечения деменции различной этиологии
US16/464,283 US20200281908A1 (en) 2016-11-28 2017-11-28 Means for treating dementia of various etiology
EA201991337A EA201991337A1 (ru) 2016-11-28 2017-11-28 Средство для лечения деменции различной этиологии

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2016146594A RU2016146594A (ru) 2016-11-28 2016-11-28 Средство для лечения деменции различной этиологии

Publications (2)

Publication Number Publication Date
RU2016146594A true RU2016146594A (ru) 2018-05-28
RU2016146594A3 RU2016146594A3 (ru) 2020-02-06

Family

ID=62196182

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016146594A RU2016146594A (ru) 2016-11-28 2016-11-28 Средство для лечения деменции различной этиологии

Country Status (4)

Country Link
US (1) US20200281908A1 (ru)
EA (1) EA201991337A1 (ru)
RU (1) RU2016146594A (ru)
WO (1) WO2018097768A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4603589A3 (en) * 2019-06-26 2025-11-19 Biorchestra Co., Ltd. Micellar nanoparticles and uses thereof
AU2021216720A1 (en) * 2020-02-07 2022-08-25 Biorchestra Co., Ltd. miRNA-485 inhibitor for gene upregulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070066552A1 (en) * 2005-01-21 2007-03-22 Introgen Therapeutics, Inc. Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
RU2457205C2 (ru) * 2010-09-07 2012-07-27 Общество С Ограниченной Ответственностью "Биофарм-Меморейн" Способ, соединение и фармацевтическая композиция и лекарственное средство для восстановления утраченной памяти в норме и патологии

Also Published As

Publication number Publication date
WO2018097768A1 (ru) 2018-05-31
RU2016146594A3 (ru) 2020-02-06
US20200281908A1 (en) 2020-09-10
EA201991337A1 (ru) 2019-11-29

Similar Documents

Publication Publication Date Title
JOP20190182B1 (ar) أسيتاميد n-] 4-فلور-5-]] (4s,2s)-2-ميثيل-4-](5-ميثيل-1،2،4-اوكسادايزول-3-يل)ميثوكسي[-1-بيبيرديل[ميثيل[ ثيازول-2-يل[ كمثبط oga
EP3646721A4 (en) DISPOSAL FILM FOR ANIMAL EXCREMENT
EA201592212A1 (ru) Кристаллические полиморфные формы свободного основания 2-гидрокси-6-((2-(1-изопропил-1н-пиразол-5-ил)пиридин-3-ил)метокси)бензальдегида
SI3097098T1 (sl) Postopek za pripravo N-((3-aminooksetana-3-il)metil)-2-(1,1-diokso- 3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-kinazolin-4-amina
CY1120454T1 (el) Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος
LT3220916T (lt) Vėžio gydymo n-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5- (etil(tetrahidro-2h-piran-4-il)amino)-4-metil-4’-(morfolinometil)-[1,1’- bifenil]-3-karboksamidu būdas
BR112017004673A2 (pt) formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida
AR103680A1 (es) Inhibidores selectivos de bace1
EP3914608A4 (en) NOVEL INSECT CONTROL PROTEINS
HUE045226T2 (hu) Herbicid hatású N-(1,3,4-oxadiazol-2-il)arilkarboxamid-származékok
HUE063043T2 (hu) Eljárás N-(5-(4-(4-formil-3-fenil-1H-pirazol-1-il)-pirimidin-2-il-amino)-4-metoxi-2-morfolinofenil)-akrilamid elõállítására
MA43685A (fr) Solutions aqueuses d'acides aminés n-acylés
EA201891342A1 (ru) Изоиндольные соединения
RU2016146594A (ru) Средство для лечения деменции различной этиологии
EP4034108A4 (en) AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS
FI3878444T3 (fi) (n-(2-((2-bentsyylifenyyli)amino)-2-oksoetyyli)-l-naftamidi) syöpälääkeaineena
PL420626A1 (pl) Nowe pochodne karbaminianów oraz ich zastosowanie
DK3288949T3 (da) Tetrahydrofuran-fusionerede aminohydrothiazin-derivater, som er anvendelige inden for behandling af Alzheimers sygdom
LT3164385T (lt) N-[2-(6-fluor-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluorpropoksi)benzilamino hidrochlorido nauja polimorfinė forma, skirta alzheimerio ligos gydymui
EP3835076A4 (en) PERSONAL IDENTIFICATION MEDIA
EP3606506A4 (en) PROCESS FOR IMPROVING THE SOLUBILITY AND BIOAVAILABILITY OF THERAPEUTICS
EP3414225C0 (en) CRYSTAL MODIFICATIONS OF N-(4,5-BISMETHANESULFONYL-2-METHYLBENZOYL) GUANIDINE HYDROCHLORIDE AND SALTS OF N-(4,5-BISMETHANESULFONYL-2-METHYLBENZOYL) GUANIDINE
TH171325A (th) อนุพันธ์เฮเทอโรไซคลิกและการใช้ของมัน
PL420629A1 (pl) Nowe pochodne karbaminianów oraz ich zastosowanie
TH180877A (th) รูปพอลิมอร์ฟชนิดใหม่ของ n-[2-(6-ฟลูออโร-1h-อิลโดล-3-อิล)เอทิล]-3-(2,2,3,3, -เตตระฟลูออโรโพรพอกซี) เบนซิลเอมีน ไฮโดรคลอไรด์ สำหรับการรักษาอัลไซเมอร์

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200824